Advances in available treatments for metastatic renal cell carcinoma affect the prevalence, morbidity, and mortality associated with skeletal-related events (SREs) owing to metastatic bone lesions. A newly published report shows that the prevalence and in-hospital mortality of SRE-associated hospitalizations are decreasing, while the associated costs are increasing.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wood, S. L. & Brown, J. E. Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat. Rev. 38, 284–291 (2012).
Lipton, A. et al. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin. Cancer Res. 10, 6397S–6403S (2004).
Molina, A. M., Motzer, R. J. & Heng, D. Y. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin. Oncol. 40, 436–443 (2013).
Antczak, C. et al. The health care burden of skeletal-related events in renal cell carcinoma patients with bone metastases. J. Urol. http://dx.doi.org/10.1016/j.juro.2013.12.042.
Botteman, M. F. et al. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom. Eur. J. Health Econ. 12, 575–588 (2011).
Maita, S. et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int. J. Cancer 130, 677–684 (2012).
Zołnierek, J. et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J. Cancer Res. Clin. Oncol. 136, 371–378 (2010).
Shih, Y. C. et al. Economic burden of renal cell carcinoma: part I--an updated review. Pharmacoeconomics 29, 315–329 (2011).
Shih, Y. C. et al. Economic burden of renal cell carcinoma in the US: part II--an updated analysis. Pharmacoeconomics 29, 331–341 (2011).
Hagiwara, M., Borker, R. & Oster, G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin. Ther. 35, 1955–1963 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Yuasa, T., Urakami, S. Decreased incidence of skeletal-related events in mRCC. Nat Rev Urol 11, 193–194 (2014). https://doi.org/10.1038/nrurol.2014.56
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.56
